Inclusion Criteria:

          -  Diagnosis of acute myeloid leukemia (AML) by World Health Organization criteria
             excluding acute promyelocytic leukemia (APL)-M3.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

          -  Participant must have adequate hematologic, renal, and liver function laboratory
             values as described in the protocol.

        Exclusion Criteria:

          -  Known central nervous system leukemia

          -  Severe chronic obstructive pulmonary disease (COPD) with hypoxemia

          -  History of any malignancy within the last 6 months except for those specified in this
             protocol and low-grade malignancies not requiring active treatment.

          -  Prior allogeneic stem cell transplant within 6 months of study drug administration and
             no requirement for graft versus host therapy.

          -  History of clinically significant medical condition that, in the opinion of the
             investigator, would adversely affect participation in this study.

          -  Known active infection with human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C.

          -  History of tumor lysis syndrome (TLS) due to previous exposure to venetoclax.